PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer

To identify a group of patients who might benefit from the addition of weekly paclitaxel to conventional anthracycline-containing chemotherapy as adjuvant therapy of node-positive operable breast cancer. The predictive value of PAM50 subtypes and the 11-gene proliferation score contained within the...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Martín, Miguel, Prat, Aleix, Rodríguez-Lescure, Álvaro, Caballero, Rosalía, Ebbert, Mark T. W., Munárriz, Blanca, Ruiz-Borrego, Manuel, Bastien, Roy R. L., Crespo, Carmen, Davis, Carole, Rodríguez, César A., López-Vega, José M., Furió, Vicente, García, Ana M., Casas, Maribel, Ellis, Matthew J., Berry, Donald A., Pitcher, Brandelyn N., Harris, Lyndsay, Ruiz, Amparo, Winer, Eric, Hudis, Clifford, Stijleman, Inge J., Tuck, David P., Carrasco, Eva, Perou, Charles M., Bernard, Philip S.
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer US 2013
Témata:
Clinical Trial
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3608881/
https://ncbi.nlm.nih.gov/pubmed/23423445
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-013-2416-2
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky